Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11905579 | 1.00 | CA9 (0.51) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL11905589 | 1.00 | CA9 (0.51) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL18220742 | 0.89 | CA12 (0.60) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL3098313 | 0.88 | KDM4E (0.49) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL23742619 | 0.86 | CA1 (0.64) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL17039830 | 0.86 | CA1 (0.64) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL30294832 | 0.86 | CA1 (0.64) | CA9CA12CA1KDM4EALDH1A1 | |
| Bromide SCHEMBL1817816 | 0.85 | CA12 (0.54) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL2204833 | 0.85 | KDM4E (0.46) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL5664318 | 0.85 | CA12 (0.58) | CA9CA12CA1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059139-A1 | COMPOUNDS FOR TREATMENT OF CANCER | THE JOHNS HOPKINS UNIVERSITY | 2025-02-20 | — | — | US | disclosed |
| EP-4452946-A2 | COMPOUNDS FOR TREATMENT OF CANCER | The Johns Hopkins University (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023122612-A2 | COMPOUNDS FOR TREATMENT OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059139-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, ACP3, TP53 | CA9 152/4885CA12 333/4885CA1 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.